The State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, China.
Adv Drug Deliv Rev. 2011 Jul 18;63(8):688-97. doi: 10.1016/j.addr.2011.02.007. Epub 2011 Mar 1.
Heart failure remains the leading cause of morbidity and mortality. Recently, it was reported that the adult heart has intrinsic regenerative capabilities, prompting a great wave of research into applying cell-based therapies, especially with skeletal myoblasts and bone marrow-derived cells, to regenerate heart tissues. While the mechanism of action for the observed beneficial effects of bone marrow-derived cells remains unclear, new cell candidates are emerging, including embryonic stem (ES) and introduced pluripotent stem (iPS) cells, as well as cardiac stem cells (CSCs) from adult hearts. However, the very low engraftment efficiency and survival of implanted cells prevent cell therapy from turning into a clinical reality. Injectable hydrogel biomaterials based on hydrophilic, biocompatible polymers and peptides have great potential for addressing many of these issues by serving as cell/drug delivery vehicles and as a platform for cardiac tissue engineering. In this review, we will discuss the application of stem cells and hydrogels in myocardial regeneration.
心力衰竭仍然是发病率和死亡率的主要原因。最近有报道称，成人心脏具有内在的再生能力，这促使人们大力研究应用基于细胞的疗法，特别是使用骨骼肌成肌细胞和骨髓来源的细胞来再生心脏组织。虽然骨髓来源细胞观察到的有益效果的作用机制尚不清楚，但新的细胞候选物不断涌现，包括胚胎干细胞 (ES) 和诱导多能干细胞 (iPS) 以及来自成人心脏的心脏干细胞 (CSC)。然而，植入细胞的极低植入效率和存活率阻止了细胞疗法成为临床现实。基于亲水、生物相容性聚合物和肽的可注射水凝胶生物材料具有很大的潜力，可以通过作为细胞/药物输送载体以及作为心脏组织工程平台来解决许多此类问题。在这篇综述中，我们将讨论干细胞和水凝胶在心肌再生中的应用。
